- Market Capitalization, $K 219,552
- Shares Outstanding, K 69,810
- Annual Sales, $ 0 K
- Annual Income, $ -18,610 K
- 60-Month Beta 0.92
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 3.91
|Period||Period Low||Period High||Performance|
| || |
-0.53 (-15.54%)since 01/27/20
| || |
+0.82 (+39.81%)since 11/27/19
| || |
+1.94 (+206.38%)since 02/27/19
Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women's healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times Square on Wednesday, February 26, 2020....
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price...
PRINCETON, N.J. (AP) _ Agile Therapeutics Inc. (AGRX) on Thursday reported a loss of $6 million in its fourth quarter.
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being...
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020
Twirla is a new non-daily, non-invasive contraceptive approved in the U.S.
Funding to Support the Company's Commercialization Plans for Twirla
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold